Stromal disrupting effects of nab-paclitaxel in pancreatic cancer Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Combined Chemotherapy Protocols
  • Fibroblasts
  • Pancreatic Neoplasms

abstract

  • These data suggest that nab-paclitaxel and gemcitabine decreases CAF content inducing a marked alteration in cancer stroma that results in tumour softening. This regimen should be studied in patients with operable PDA.

publication date

  • August 20, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3749580

Digital Object Identifier (DOI)

  • 10.1038/bjc.2013.415

PubMed ID

  • 23907428

Additional Document Info

start page

  • 926

end page

  • 33

volume

  • 109

number

  • 4